menu search

Loan-to-grant and microgrant programs benefit scranton businesses

Less than two months after opening its doors to beer enthusiasts in downtown Scranton, mutant Brewing i...

October 31, 2023, 12:44 am

Seelos therapeutics to present a poster on sls-005 in alzheimer's disease at neuroscience 2023

-SLS-005 induces autophagy to reduce mutant protein aggregates, and is currently being studied in Alzhe...

October 27, 2023, 8:11 am

Mattel (mat) unveils new toy-line with paramount tie-up

Mattel (MAT) announces collaboration with Paramount's Teenage mutant Ninja Turtles to develop The Maste...

October 18, 2023, 12:03 pm

Paramount global's (para) teenage mutant ninja game returns

Paramount Global (PARA) announces the return of its famous game, Teenage mutant Ninja Turtles & Other S...

October 16, 2023, 12:48 pm

Fda approves pfizer's (pfe) braftovi + mektovi for lung cancer

Pfizer's (PFE) Braftovi + Mektovi drug combo gets label expansion for BRAF V600E-mutant non-small cell ...

October 13, 2023, 1:31 pm

Pfizer's lung cancer combination therapy approved by the fda

Pfizer Inc (NYSE:PFE) announced that the United States Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) plus MEKTOVI (binimetin...

October 12, 2023, 8:41 am

Kura's ziftomenib: the swiss army knife in aml therapy

Kura Oncology's lead candidate, ziftomenib, shows dual-functionality in treating NPM1-mutant AML and ov...

September 25, 2023, 4:40 am

Exelixis to license insilico ai-designed cancer drug

Exelixis Inc. EXEL, -0.54% is licensing the global rights to develop and commercialize an investigational cancer treatment that was derived from Insil...

September 12, 2023, 8:40 am

Eli lilly reports positive results from study of thyroid cancer treatment

Eli Lilly & Co. LLY, +0.66% on Tuesday reported positive results from a study evaluating its targeted therapy Retevmo versus the current standard init...

August 22, 2023, 8:32 am

Kura oncology presents late-breaking clinical data for menin inhibitor ziftomenib at 2023 european hematology association (eha) congress

– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (...

June 11, 2023, 7:45 am

Verastem: updated avutometinib data brings my position out of mothballs

Verastem Oncology presented promising data from their RAMP 201 program of Avutometinib monotherapy or in combination with Defactinib for the treatment...

June 11, 2023, 4:20 am

Panbela announces clinical trial with moffitt cancer center for phase i/ii program in stk11 mutant non-small cell lung cancer

MINNEAPOLIS, May 22, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics ...

May 22, 2023, 12:15 pm

Frontier medicines presents new preclinical data on its development candidate, fmc-376, a dual krasg12c inhibitor, at the 2023 aacr annual meeting

-FMC-376 is a highly selective, direct dual inhibitor designed to rapidly and completely block both the active and inactive forms of KRASG12C and over...

April 16, 2023, 7:00 pm

C4 therapeutics announces first patient dosed in phase 1/2 clinical trial evaluating cft1946, an orally bioavailable bidac™ degrader, in braf v600 mutant solid tumors

WATERTOWN, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated ...

January 30, 2023, 12:00 pm

Biomea (bmea) begins dosing in lung cancer study, stock up

Biomea Fusion (BMEA) announces the successful dosing of the first patient in phase I/Ib study of BMF-219 in KRAS ...

January 18, 2023, 12:48 pm

Kura oncology presents updated clinical data from komet-001 trial of menin inhibitor ziftomenib at american society of hematology annual meeting

– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency ...

December 10, 2022, 3:30 pm

Immuneering (imrx) files ind for cancer candidate imm-1-104

Immuneering (IMRX) files an investigational new drug (IND) application to the FDA to start a phase I/IIa study on IMM-1-104 for the treatment of advan...

September 5, 2022, 12:02 pm

Karyopharm to present new selinexor data at the 2022 american society of clinical oncology annual meeting

– Encouraging Initial Data Observed in Phase 1/2 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Fav...

May 26, 2022, 5:08 pm

Astrazeneca cancer drug receives priority fda review as data points to its potential in lung cancer

AstraZeneca PLC (LSE:AZN) said its drug Enhertu has been granted a priority review by US regulators following the release of data underlining its pote...

April 19, 2022, 3:49 am

Jazz pharmaceuticals to present pan-raf inhibitor pre-clinical data at american association for cancer research (aacr) 2022 annual meeting

DUBLIN, March 8, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that pre-clinical data on JZP815, an investigational, ne...

March 8, 2022, 4:35 pm


Search within

Pages Search Results: